Who We Are
Pharmaceutical raw materials and active pharmaceutical ingredients manufacturers
Tianming Pharmaceutical is a leading company in the research, development, production, and sales of new drugs. Specializing in chemical intermediates, pharmaceutical chemicals, and raw materials, we are trusted active pharmaceutical ingredient suppliers for antibiotics, cardiovascular, diabetes, anti-tumor, anti-aging, and antiviral drugs.
What We Do
Transforming Health with Premium Pharmaceutical Solutions
Advanced Drug R&D
Our team pioneers in discovering and developing new drugs, focusing on antibiotics, cardiovascular, diabetes, anti-tumor, anti-aging, and antiviral treatments.
High-Quality Manufacturing
We maintain rigorous quality control across all production processes, guaranteeing the highest standards for our chemical intermediates and pharmaceutical raw materials.
Comprehensive Global Distribution
We provide active pharmaceutical ingredients, technical consulting, collaborative R&D and other services to global customers to meet diverse market needs.
Our Products
Popular categories
Antiviral
Antiviral products and their intermediates (baloxavir fumarate, nafamostat mesylate, mupiravir, etc.)
Diabetes
Diabetes API and their intermediates (alogliptin, linagliptin, empagliflozin, etc.)
Anti-tumor
Anti-tumor API and their intermediates (ibrutinib, baricitinib, tofacitinib, etc.)
Cardiovascular
Cardiovascular API and their intermediates (LCZ696, AHU377 calcium salt, etc.)
What's News
Latest News at Tianming
The Proven Decision Tree For A Supplier Change Notice
A buyer-side decision tree for handling an intermediate supplier change notice — what to accept, contest, or reject, and how to log the call.
What Powerful Buyers Do Before A Supplier Discontinuation
A supplier discontinuation is a deadline, not just bad news. The questions to ask in writing, the last-time-buy calculation, and the files to collect in time.
Ultimate Questions To Ask Before You Reject A Batch
Rejected batch? What to do in the first hour, how to write the notice, who pays the costs, and the escalation path when a supplier stalls.